rs2248932 — BLK Promoter/Intronic

Intronic BLK variant in the FAM167A-BLK regulatory locus that reduces B-lymphoid kinase expression and independently raises risk for systemic lupus erythematosus and related autoimmune diseases

See your personal result for BLK

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

BLK rs2248932 — A Second Signal in the B-Cell Kinase Locus

BLK (B-lymphoid tyrosine kinase)11 BLK (B-lymphoid tyrosine kinase)
A Src-family non-receptor tyrosine kinase expressed almost exclusively in B cells and plasmacytoid dendritic cells is the kinase that drives B-cell receptor (BCR) signaling and enforces the central tolerance checkpoint that eliminates self-reactive B cells. rs2248932 sits in intron 1 of BLK within the FAM167A-BLK regulatory locus on chromosome 8p23.1 — the same locus as the more-studied rs13277113 — but has been shown to carry an independent association signal with systemic lupus erythematosus (SLE) and related autoimmune conditions. The A allele reduces BLK expression in B cells, paralleling the mechanism of its locus-partner rs13277113, and is more common in East Asian than in European populations.

The Mechanism

The FAM167A-BLK locus at chr8p23.1 harbors a cluster of regulatory variants that modulate BLK transcription in B cells. rs2248932 lies in the first intron of BLK, a region that contains enhancer elements22 enhancer elements
DNA sequences that bind transcription factors and boost gene expression, typically located in introns or flanking regions rather than the coding sequence that respond to B-cell-specific transcription factor binding. The A allele at rs2248932 is associated with reduced BLK mRNA levels in B-cell lines, consistent with a regulatory effect on this intronic enhancer. When BLK expression is reduced, the tolerance checkpoint33 tolerance checkpoint
The process in the bone marrow and periphery by which B cells that recognize self-antigens are normally eliminated or functionally silenced is partially impaired: self-reactive B cells escape deletion at a higher rate and can subsequently produce autoantibodies against nuclear antigens (anti-dsDNA, anti-Smith in SLE) or other self-proteins.

While rs2248932 and rs13277113 are both located in the FAM167A-BLK regulatory region and both associate with SLE, studies using conditional analysis have suggested they may tag partially independent regulatory elements or haplotypes within the locus. The A allele of rs2248932 also shows notably different population frequencies than rs13277113: the A allele reaches ~72.7% in East Asian populations, making it the major allele in those groups — consistent with the higher SLE incidence in East Asian women44 higher SLE incidence in East Asian women
Estimated 2–3× higher SLE prevalence and incidence in East Asian populations compared to Europeans, partially explained by a higher burden of risk alleles at loci like FAM167A-BLK globally.

The Evidence

The clearest evidence comes from two large meta-analyses. Fan et al. 201155 Fan et al. 2011
Six studies, 11,796 SLE cases and 20,271 controls was the first dedicated meta-analysis of rs2248932, finding a genome-wide significant A-allele OR of 1.264 (95% CI 1.208–1.322) with no heterogeneity across studies. A larger Song & Lee 2017 meta-analysis66 Song & Lee 2017 meta-analysis
17 studies, 22,701 SLE cases, 36,365 controls, extending the Fan 2011 analysis with additional Asian and Caucasian cohorts confirmed OR=1.285 (95% CI 1.228–1.345, p<1×10⁻⁸), consistent across both Caucasian and Asian populations.

The Chinese Han replication by Zhang et al. 201077 Zhang et al. 2010
1,396 SLE cases and 4,362 controls from mainland China demonstrated an association at p=1.41×10⁻⁸ and highlighted a key epidemiological observation: the A risk allele is the major allele in East Asian populations (allele frequency ~72–73%), versus only ~35% in Europeans. This population gradient mirrors the geographic distribution of SLE incidence and helps explain why East Asian women have the highest global SLE burden.

The association extends beyond SLE. Yin et al. 202188 Yin et al. 2021
Chinese NMOSD cohort found the G allele (protective, non-risk) significantly underrepresented in neuromyelitis optica spectrum disorder (NMOSD) patients (OR=0.57, p=0.003), with a stronger effect in AQP4-antibody-positive cases (OR=0.46, p=0.001). These findings confirm that A-allele-driven BLK downregulation broadly predisposes to B-cell-mediated neural autoimmunity as well as systemic autoimmune disease.

Not all autoimmune associations replicate uniformly. A Chinese Han primary Sjögren's syndrome study99 Chinese Han primary Sjögren's syndrome study
Salgado et al. 2013 found no significant association of rs2248932 with Sjögren's in that cohort, suggesting the effect may be trait-specific, population-specific, or attenuated in Sjögren's relative to SLE.

The overall evidence level is strong: replicated across large independent cohorts, consistent effect sizes, no publication bias detected in the Fan 2011 analysis, biologically plausible mechanism through BLK expression reduction, and OR well above 1.2 in the largest available meta-analyses.

Practical Implications

Carriers of the A allele — particularly AA homozygotes — carry a modestly elevated background risk for B-cell-driven autoimmune diseases, primarily SLE. The per-allele OR of ~1.26–1.29 translates to a meaningful cumulative risk when combined with co-occurring risk alleles at the same locus (rs13277113) or interacting loci (BANK1 rs10516487, PTPN22 rs2476601). In practice, the most important steps are recognizing early autoimmune warning signs and ensuring timely diagnosis, since SLE, NMOSD, and related conditions are all highly treatable when caught early but can cause irreversible organ damage when delayed.

There are no supplement or dietary interventions proven to counteract BLK-mediated B-cell dysregulation. Actionable recommendations focus on monitoring, early symptom recognition, and avoidance of known autoimmune triggers (UV radiation, smoking).

Interactions

rs2248932 and rs13277113 are both within the FAM167A-BLK regulatory locus and both reduce BLK expression via the A risk allele. Carrying A alleles at both variants compounds the BLK expression deficit additively — individuals who are A-risk at both loci show the greatest reduction in BLK mRNA. The clinical consequence is a substantially higher combined autoimmune risk than either variant alone explains.

Beyond the same locus, the most important trans-gene interaction is with BANK1 rs105164871010 BANK1 rs10516487
BANK1 encodes B-cell scaffold protein with ankyrin repeats; the G risk allele at rs10516487 (R61H) enhances BCR signaling, synergizing with BLK deficiency to push B-cell hyperactivation. Studies of Sjögren's syndrome show combined BLK-BANK1 risk allele carriers with OR=2.36 (P<0.0001), far exceeding the individual variant effects. If you also carry the PTPN22 rs2476601 A allele (R620W), this further amplifies the autoimmune B-cell and T-cell threshold shift.

Genotype Interpretations

What each possible genotype means for this variant.

GG Lower-Risk Genotype Normal

Protective genotype — higher BLK expression, typical autoimmune risk

You carry two copies of the G allele at BLK rs2248932, the genotype associated with the highest BLK expression at this locus. Your BLK gene activity in B cells is undiminished by this variant, supporting robust B-cell tolerance signaling. About 39% of people globally share this genotype, though it is more common in European and African populations (~43% and ~33% respectively) and considerably rarer in East Asian populations (~7.5%). Your background genetic risk for BLK-associated autoimmune diseases from this variant is at or below population average.

AG One Risk Allele Intermediate

One BLK risk allele — modestly reduced B-cell tolerance signaling

The A allele at rs2248932 is a regulatory variant in intron 1 of BLK, within the FAM167A-BLK locus at chr8p23.1. It reduces BLK gene expression in B cells through an effect on intronic regulatory elements. This BLK expression reduction — even partial in heterozygotes — shifts the B-cell tolerance set-point: self-reactive B cells that would normally be eliminated in the bone marrow survive more often, potentially contributing to autoantibody production years before clinical disease emerges.

The heterozygous AG genotype confers approximately the same per-allele OR as homozygous AA under the additive model documented across multiple meta-analyses. Fan et al. 2011 (6 studies) and Song & Lee 2017 (17 studies) both confirm A-allele ORs of approximately 1.26–1.29 for SLE in populations spanning Caucasians and East Asians. The NMOSD data (Yin et al. 2021) confirms a parallel signal in neural B-cell autoimmunity.

AA Two Risk Alleles High Risk

Two BLK risk alleles — meaningfully elevated autoimmune risk

The homozygous AA genotype produces the lowest BLK expression of the three genotypes at this locus. The combined dose of two A alleles means BLK-dependent B-cell tolerance signaling is most severely compromised. Self-reactive B cells that escape bone marrow deletion can subsequently encounter self-antigens in peripheral tissues and initiate autoantibody production — a process called "pre-clinical autoimmunity" that may precede clinical diagnosis by years.

The dramatic difference in AA genotype frequency by ancestry (53% in East Asians vs 12% in Europeans) is one of the genetic factors contributing to the well-documented 2–3× higher SLE incidence and prevalence in East Asian populations globally. In Chinese Han populations, the A allele frequency at rs2248932 (~72.7%) is among the highest reported for a documented SLE risk locus.

The AA genotype compounds with rs13277113 A-allele at the same locus. Individuals who are AA at both loci face an additive BLK expression deficit that substantially exceeds the effect of either variant individually. Additionally, the BANK1 rs10516487 interaction (documented at OR=2.36 for Sjögren's syndrome in BANK1-BLK co-risk carriers) is relevant here: if you also carry BANK1 risk alleles, your B-cell receptor signaling threshold is doubly perturbed from both BLK deficiency and BANK1 hyperactivation.

Beyond SLE, the AA genotype is associated with an elevated risk for NMOSD (the G protective allele is absent), and the locus has been studied in polymyositis/dermatomyositis in Chinese Han populations, further extending its autoimmune relevance.